METASTATIC BREAST CARCINOMA

This phase 3 trial tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. The study included 608 adults whose breast cancer had spread locally …

This early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…

This early-stage trial tests a combination of two drugs, cyclophosphamide and veliparib, in 35 people with HER2-negative breast cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see how well the drugs work together to stop tumor growt…

This study tested whether adding an immunotherapy drug (pembrolizumab) to standard hormone therapy (letrozole) and a targeted drug (palbociclib) could shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor-positive breast cancer. The 47 participants…

This study tests whether adding a drug called copanlisib to the usual two-drug therapy (fulvestrant and abemaciclib) works better for people with a certain type of advanced breast cancer (hormone receptor-positive, HER2-negative) that has spread. About 24 participants will receiv…

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…

This study tests whether a drug called olaparib, which blocks cancer cells from repairing themselves, works better alone or when combined with an immunotherapy drug (atezolizumab) for people with advanced breast cancer that has a specific genetic change (BRCA mutation). About 81 …

This study looks at whether a type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. About 138 adults with hormone receptor-positive, HER2-known breast cancer that is mostly in the bones will get the scan before a…

This trial is testing whether a substance called GM1 can prevent or reduce nerve damage caused by paclitaxel chemotherapy. The study involves about 100 people with metastatic breast cancer who are receiving paclitaxel treatment. Researchers want to see if giving GM1 alongside che…

This study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if this could help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid t…

This study aims to create a large collection of blood and tumor samples from 300 people whose breast cancer has spread or returned. By linking these samples with medical information, researchers hope to learn why the cancer spreads and why people respond differently to treatments…

This study tests whether watching a short video helps people with metastatic cancer understand tumor genomic testing better. About 243 adults with cancer that has spread will watch the video and answer questions before and after. The goal is to see if the video improves knowledge…